![Company](https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_CMN_Companies_to_Follow_2023_01_17_81d7a58868_1c503a0f51.png)
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Verve Therapeutics
Main focus: Gene editing for the treatment of genetic cardiovascular diseases
Company stage: Pre-clinical
Diseases: Heterozygous familial hypercholesterolemia, familial hypercholesterolemia
Genome editing technology: Base editing, CRISPR-Cas9, CRISPR-Cas12a
Funding stage: Public (NASDAQ:VERV)
Location: Cambridge, MA, USA
Website: https://www.vervetx.com/
Pipeline: https://www.vervetx.com/pipeline/
Partners: Beam Therapeutics
![](https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_verve_a4b1cebd4e_ad5310ca70.jpg)
Verve Therapeutics is a pre-clinical stage gene-editing company that focuses on developing novel therapies for genetic cardiovascular diseases. The company holds multiple licenses from The Broad Institute and has also licensed base-editing technology from Beam Therapeutics. The company is initially focusing on PCSK9 and ANGPTL3 as targets.